Magdalena biosciences, a joint venture between jaguar health and filament health, to present october 16 at bio investor forum

Magdalena aiming to submit investigational new drug (ind) application in early 2025 to the fda for a next-generation psychoactive prescription drug candidate for potential mental health indications such as adhd and schizophrenia, with 1-2 additional ind applications filed in 2025 san francisco, ca / accesswire / october 10, 2024 / jaguar health, inc. (nasdaq:jagx) today announced that dr. karen brunke, jaguar's evp of corporate and business development and acting ceo of magdalena biosciences, inc. (magdalena), the joint venture recently formed by jaguar and filament health corp. (otcqb:flhlf)(cboe ca:fh)(fse:7qs) to develop novel, natural prescription medicines derived from plants for mental health indications, is presenting on wednesday, october 16, 2024 at 10:15 a.m. pdt at the bio investor forum, which takes place october 15-16 in san francisco, california.
JAGX Ratings Summary
JAGX Quant Ranking